Short Interest in Biorestorative Therapies, Inc. (NASDAQ:BRTX) Drops By 78.5%

Biorestorative Therapies, Inc. (NASDAQ:BRTX) was the recipient of a large drop in short interest in the month of August. As of August 14th, there was short interest totaling 99,687 shares, a drop of 78.5% from the July 30th total of 463,966 shares. Approximately 0.5% of the shares of the stock are short sold. Based on an average daily trading volume, of 298,477 shares, the short-interest ratio is currently 0.3 days.

Biorestorative Therapies Price Performance

Shares of BRTX traded down $0.00 during midday trading on Friday, reaching $0.20. The stock had a trading volume of 176,866 shares, compared to its average volume of 7,547,845. The company has a market capitalization of $5.17 million, a P/E ratio of -0.19 and a beta of 0.79. The firm’s 50 day moving average price is $0.29 and its 200-day moving average price is $0.29. Biorestorative Therapies has a 52 week low of $0.16 and a 52 week high of $1.89.

Hedge Funds Weigh In On Biorestorative Therapies

Several large investors have recently made changes to their positions in BRTX. Virtu Financial LLC raised its holdings in shares of Biorestorative Therapies by 102.4% in the 3rd quarter. Virtu Financial LLC now owns 24,351 shares of the company’s stock worth $35,000 after purchasing an additional 12,319 shares in the last quarter. DRW Securities LLC bought a new stake in Biorestorative Therapies during the fourth quarter worth approximately $55,000. Finally, Citadel Advisors LLC acquired a new position in Biorestorative Therapies in the third quarter worth approximately $152,000. Institutional investors own 69.38% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Biorestorative Therapies in a research note on Monday. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has an average rating of “Sell”.

About Biorestorative Therapies

Biorestorative Therapies Inc (NASDAQ: BRTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of regenerative tissue therapy products. The company leverages a proprietary universal allogeneic cell technology platform to create high-potency cell therapy candidates designed to promote tissue repair, reduce inflammation and accelerate healing in areas damaged by disease or medical treatment.

Its lead development program targets radiation-induced oral mucositis (RIOM), a painful and dose-limiting side effect experienced by head and neck cancer patients undergoing radiotherapy.